Nuvalent, Inc.

Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted small molecule kinase inhibitors for patients with cancer. The company leverages deep expertise in chemistry and structure-based drug design to develop innovative therapies that aim to overcome treatment resistance, minimize off-target adverse events, and address brain metastases in patients with molecularly defined cancers. Nuvalent's pipeline is primarily focused on thoracic oncology, with lead programs targeting ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), as well as a HER2-selective program. The company is currently transitioning from a development-stage entity toward a commercial-stage precision oncology franchise, with multiple regulatory milestones and potential product launches anticipated in 2026.